Group 1 - Yunfeng Financial Holdings (00376) reported an increase in shareholding from 1.636 billion shares to 1.828 billion shares, raising its holding percentage from 42.30% to 45.02% [2] - Wan Ke Yi Lian (01762) maintained its shareholding at 420 million shares, with a slight increase in holding percentage from 23.73% to 23.74% [2] - Stone Four Pharmaceutical Group (02005) increased its shareholding from 1.198 billion shares to 1.203 billion shares, with a rise in holding percentage from 40.58% to 40.75% [2] Group 2 - Guichuang Tongqiao-B (02190) saw a decrease in shareholding from 19.3872 million shares to 15.8872 million shares, with a decline in holding percentage from 6.01% to 4.93% [2] - Multiple entities, including Key Imagination Limited and Yunfeng Financial Holdings Limited, reported the same increase in shareholding for Yunfeng Financial Holdings [2] - The changes in shareholding may be influenced by corporate actions such as rights issues, consolidations, or splits [2]

Core Viewpoint - The company, Guichuang Tongqiao (02190.HK), has been actively repurchasing its shares, indicating a potential strategy to enhance shareholder value and confidence in its stock performance [1] Summary by Relevant Sections Share Buyback Activity - On September 23, the company spent HKD 1.214 million to repurchase 50,000 shares [1] - On September 22, the company spent HKD 1.245 million to repurchase another 50,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份 ...

中期報 告 202 5 Interim Report 202 5 Interim Report 2025 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務及業務摘要 | 4 | | 管理層討論及分析 | 5 | | 企業管治及其他資料 | 32 | | 中期財務資料的審閱報告 | 47 | | 中期簡明綜合全面收益表 | 48 | | 中期簡明綜合資產負債表 | 49 | | 中期簡明綜合權益變動表 | 51 | | 中期簡明綜合現金流量表 | 52 | | 中期簡明綜合財務資料附註 | 53 | | 釋義 | 87 | 頁數 公司資料 董事會 於最後實際可行日期，董事會成員如下： 執行董事 趙中博士 （董事長） 謝陽先生 李崢博士 非執行董事 李東方先生 王大松博士 獨立非執行董事 計劍博士 邱妘女士 錢湘博士 聯席公司秘書 袁泉衛先生 關秀妍女士 授權代表 趙中博士 關秀妍女士 監事 馬長安先生 （主席） 劉濤先生 王宏波女士 審計委員會 邱妘女士 （主席） 計劍博士 錢湘博士 薪酬委員會 計劍博士 （主席） 李東方先生 錢湘博士 提名委員會 趙中博士 （主席） 邱妘女士 計 ...

格隆汇9月22日丨归创通桥(02190.HK)公告，9月22日耗资124.5万港元回购5万股。 ...

智通财经APP讯，归创通桥(02190)发布公告，于2025年9月22日，该公司斥资124.51万港元回购5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年9月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

智通财经APP讯，归创通桥(02190)公布，2025年9月18日耗资约129.04万港元回购5万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年9月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...